United States · FDA National Drug Code directory

Ondansetron

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
76420-056_5a14bcb1-466d-9cbf-e063-6394a90a5550
Product NDC
76420-056
Form
TABLET, ORALLY DISINTEGRATING
Composition / generic term
Ondansetron
Labeler
Asclemed USA, Inc.
Marketing category
ANDA
Marketing start / end (source format)
20100412
Source listing expiry
20271231

Source-listed ingredients

  • ONDANSETRON — 4 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 4 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (76420-056-04) · 76420-056-04
  • 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (76420-056-06) · 76420-056-06
  • 8 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (76420-056-08) · 76420-056-08
  • 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (76420-056-10) · 76420-056-10
  • 20 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (76420-056-20) · 76420-056-20
  • 30 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (76420-056-30) · 76420-056-30

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →